ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

VTGN VistaGen Therapeutics Inc

4.55
0.14 (3.17%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.14 3.17% 4.55 23:00:08
Open Price Low Price High Price Close Price Previous Close
4.47 4.31 4.55 4.50 4.41
more quote information »

Recent News

Date Time Source Heading
4/25/202407:30BWVistagen Announces Positive Results from Phase 2A Pilot..
4/09/202407:30BWVistagen to Present at the 2024 Anxiety and Depression..
4/01/202407:30BWVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol..
3/11/202407:30BWVistagen to Present at Stifel 2024 Virtual CNS Days
3/06/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/29/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
2/28/202407:30BWVistagen to Present at TD Cowen 44th Annual Health Care..
2/14/202417:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202415:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/14/202407:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202415:52EDGAR2Form S-3 - Registration statement under Securities Act of..
2/13/202415:33EDGAR2Form 8-K - Current report
2/13/202415:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2/13/202415:20BWVistagen Reports Fiscal 2024 Third Quarter Financial Results..
2/06/202407:30BWVistagen to Report Fiscal Year 2024 Third Quarter Financial..
1/03/202416:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/03/202416:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/03/202416:09EDGAR2Form 8-K - Current report
12/27/202307:30BWVistagen Receives Notice from European Patent Office of..
11/09/202315:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202315:42EDGAR2Form 8-K - Current report
11/09/202315:30BWVistagen Provides Corporate Update and Reports Fiscal 2024..
11/08/202307:30BWVistagen to Present at Stifel 2023 Healthcare Conference
11/07/202307:30BWVistagen to Present Positive Fasedienol Phase 3 Data and..
11/06/202320:46EDGAR2Form 8-K/A - Current report: [Amend]
11/06/202315:27EDGAR2Form 8-K - Current report
11/06/202307:00BWVistagen To Report Second Quarter Financial Results and Host..
11/03/202319:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
10/26/202315:13EDGAR2Form 8-K - Current report
10/16/202315:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/16/202315:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/06/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/06/202315:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/05/202315:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/05/202307:30BWVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro..
10/04/202315:07EDGAR2Form 8-K - Current report
10/03/202315:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/02/202306:30BWVistagen Announces Pricing of $100 Million Underwritten..
10/02/202306:15EDGAR2Form 8-K - Current report
9/29/202315:26EDGAR2Form 8-K - Current report
9/12/202307:30BWVistagen Announces Positive Results from Exploratory Phase..
9/08/202316:27EDGAR2Form 8-K - Current report
9/05/202308:00BWVistagen and Fuji Enter Exclusive Negotiation Agreement for..
8/23/202312:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/23/202312:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
8/22/202307:40EDGAR2Form 8-K - Current report
8/22/202307:30BWVistagen Appoints Cindy Anderson as Chief Financial Officer

Your Recent History

Delayed Upgrade Clock